Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer-Reference-Cited by-同舟云学术

Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer

Published:2014-02 Issue:2 Volume:83 Page:211-218
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Pujol Jean-Louis,Pirker Robert,Lynch Thomas J.^ORCID,Butts Charles A.,Rosell Rafael,Shepherd Frances A.,Vansteenkiste Johan,O’Byrne Kenneth J.,de Blas Barbara,Heighway Jim,von Heydebreck Anja,Thatcher Nick

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference39 articles.

1. The new World Health Organization classification of lung tumours;Brambilla;Eur Respir J,2001

2. Prospective population-based study on the survival of patients with lung cancer;Makitaro;Eur Respir J,2002

3. Population variations in the initial treatment of non-small-cell lung cancer;Potosky;J Clin Oncol,2004

4. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21;Zhu;J Clin Oncol,2008

5. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion;Bunn;Oncologist,2008

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer;Cancer Treatment Reviews;2024-01

2. Resistance of Lung Cancer to EGFR-Specific Kinase Inhibitors: Activation of Bypass Pathways and Endogenous Mutators;Cancers;2023-10-16

3. L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab;Cell Reports Medicine;2023-08

4. Sex-specific differences of special tumor diseases;Die Innere Medizin;2023-07-17

5. Final results of the IFCT-0803 study, a phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small-cell lung cancer;Cancer/Radiothérapie;2022-09